Power Law company profile

TESARO

Biotech & Life Sciences · Waltham, United States · Founded 2010 · IPO 2012 Unicorn

Providing transformative therapies to people bravely facing cancer

Valuation

$5.10B

Market cap · 2026

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

3 investors on TESARO's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

NEA

Series B+ 2 investors entered at this stage

Kleiner Perkins

Sofinnova Investments

Global footprint

Where TESARO has talent and traffic

Workforce by country

6 countries with
team presence

🇺🇸 United States73.4%

🇫🇷 France11.9%

🇩🇪 Germany4.8%

🏳️ Mauritius3.3%

🇬🇧 United Kingdom3.3%

Top 5 of 6 shown

Patent intelligence

$39M patent portfolio · 27 active families

Estimated portfolio value

$39M

0.77% of market cap · 3.4× smaller than top peer Deciphera Pharmaceuticals ($133M)

27 active patent families

Where TESARO innovates Cancer researchCarcinosisOncologyMolecular biologyImmunology

Where TESARO concentrates vs peers

Each axis is a top-10 topic across TESARO and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about TESARO

An AI-synthesized read of the highest-engagement posts about TESARO on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See TESARO on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles